Search companies on Owler
Advanced Search
Latest news
Newsfeed
My followed companies
Followed Companies
2 Followers on Owler
OverviewCompetitorsAcquisitionsFundingNews & Insights

Mirum

Mirum researches, develops and commercializes novel therapies for the treatment of liver diseases. Read more

Chris Peetz's photo - President & CEO of Mirum

President & CEO

Chris Peetz

CEO Approval Rating

90/100

Founded:

2018

Status:

PublicIndependent CompanyNASDAQMIRM

SIC Code:

2834 NAICS listing »

Website:

Annual Revenue
Employees
Sector
Pharmaceuticals
Headquarters

MIRUM TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

The top 10 competitors in Mirum's competitive set are GENFIT, Akero Therapeutics, Cyta Therapeutics, Inc., CymaBay, Cirius Therapeutics, Blade Therapeutics, Exalenz, NGM Bio, Innate Pharma. Together they have raised over 17.0B between their estimated 127.3K employees. Mirum has 33 employees and is ranked 12th among it's top 10 competitors. The top 10 competitors average 7,166.

GENFIT is Mirum's top competitor. GENFIT is a Public company that was founded in Loos, Nord-Pas-de-Calais in 1999. GENFIT operates in the Biotechnology industry. GENFIT has 97 more employees vs. Mirum.

Akero Therapeutics has been one of Mirum's top competitors. Akero Therapeutics is headquartered in South San Francisco, California, and was founded in 2017. Akero Therapeutics is in the Biotechnology industry. Akero Therapeutics generates NaN% the revenue of Mirum.

Cyta Therapeutics, Inc. is perceived as one of Mirum's biggest rivals. Cyta Therapeutics, Inc. was founded in null in , . Cyta Therapeutics, Inc. competes in the field. Cyta Therapeutics, Inc. generates $ less revenue than Mirum.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Cirius Therapeutics a competitor of Mirum?

I don't know

Trending News for Mirum and Mirum's Competitors

June 21, 2021

MarketScreener

Genfit : This document has been translated in English for information only. In the event of any differences between the French text and the English text, the French language version shall supersede (Form 6-K)

(marketscreener.com) This document has been translated in English for information only. In the event ... See more »

June 21, 2021

Benzinga

Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients

Akero Therapeutics Inc (NASDAQ: AKRO) has announced additional analyses from its Phase 2a BALANCED st... See more »

June 22, 2021

Clinical Trials Arena

Gilead's Veklury lowers Covid-19 death risk in real-world studies

The post Gilead's Veklury lowers Covid-19 death risk in real-world studies appeared first on Clinical... See more »

Mirum Quarterly and Annual Revenue

Coming soon for Mirum!

Annual Revenue

Mirum Acquisitions

No recent acquisitions found related to Mirum

Mirum Funding History

Since Mirum was founded in 2018, it has participated in 2 rounds of funding. In total Mirum has raised $195.0M. Mirum's last funding round was on Jul 2019 for a total of $75.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jul 2019
$75M

Series A
Nov 2018
$120M

New Enterprise Associates

Total Funding: $195M

Since Mirum was founded in 2018, it has participated in 2 rounds of funding. In total Mirum has raised $195.0M. Mirum's last funding round was on Jul 2019 for a total of $75.0M

Mirum Investments

No recent investments found related to Mirum

Mirum News

May 11, 2021BioSpace

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 11, 2021

Mirum Pharmaceuticals, Inc. announced that on May 10, 2021, the Compensation Committee of Mirum's Boa... See more »
May 9, 2021Seeking Alpha

Mirum Pharmaceuticals' (MIRM) CEO Chris Peetz on Q1 2021 Results - Earnings Call Transcript

See more »
May 6, 2021Zacks

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.75% and -100.00%,... See more »
April 26, 2021MarketScreener

Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome

(marketscreener.com) - Methods of use patent expected to provide patent protection through 2040. http... See more »
April 12, 2021BioSpace

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet's Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis

- Mirum expands potential opportunities across rare disease pipeline - Vivet to lead pre-clinical dev... See more »
April 12, 2021BioSpace

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 12, 2021

Mirum Pharmaceuticals, Inc. announced that on April 12, 2021, the Compensation Committee of Mirum's B... See more »
March 9, 2021BioSpace

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced financial results for the fourth quarter ... See more »

Mirum Press Releases

April 29, 2021Business Wire

Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases

FOSTER CITY, Calif. & BEIJING--(BUSINESS WIRE)--CANbridge and Mirum Enter into Licensing Agreement to... See more »
April 29, 2021Business Wire

Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Report First Quarter 2021 Financial Re... See more »
March 29, 2021Business Wire

Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Appl... See more »
February 22, 2021Business Wire

Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Upcoming Investor Conferenc... See more »
November 30, 2020Business Wire

Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces European Medicines Agency Valid... See more »
November 16, 2020StreetInsider

Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat

- Results of long-term treatment from the ITCH and IMAGINE II studies presented in late-breaking oral... See more »
September 1, 2020Business Wire

Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum initiates rolling NDA submission for maralixibat for the ... See more »

Mirum Videos

October 21, 2019Mirum Youtube Channel

"Mirum PFIC Series: Kearns Family" on YOUTUBE

See more »

Social Media

Mirum Headquarters

950 Tower Lane Suite 1050

Foster City, California94404

1-650-667-4085

Driving Directions »

Trending Companies

Mirum Summary

ABOUT

Overview

Mirum researches, develops and commercializes novel therapies for the treatment of liver diseases. Mirum was founded in 2018. Mirum's headquarters is located in Foster City, California, USA 94404. It has raised 195.0M in 2 rounds. The latest round was...

CEO

Mirum's President & CEO, Chris Peetz, currently has an approval rating of 90%. Mirum's primary competitors are GENFIT, Akero Therapeutics & Cyta Therapeutics, Inc..

Frequently Asked Questions about Mirum

  1. When was Mirum founded?

    Mirum was founded in 2018

  2. Who is Mirum's CEO?

    Mirum's CEO is Chris Peetz

  3. How much revenue does Mirum generate?

    Mirum generates $ < 1M in revenue

  4. How much funding does Mirum have?

    Mirum has historically raised $195M in funding

  1. Where is Mirum's headquarters?

    Mirum's headquarters is in Foster City California, USA

  2. How many employees does Mirum have?

    Mirum has 33 employees

  3. What sector does Mirum operate in?

    Mirum is in Pharmaceuticals

  4. Who are Mirum's competitors?

    Mirum's top competitors are GENFIT, Akero Therapeutics, Cyta Therapeutics, Inc.
Stay up-to-date with the latest news on Mirum

© 2021 Owler, Inc.